Revolution Medicines

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Earnings data Q1 2023

Earnings data Q2 2023

Underwriters' full exercise of option brings gross proceeds to $345.0 million Underwriters' full exercise of option brings gross proceeds to $345.0 million

Revolution Medicines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

REWOOD CITY, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the pricing of its underwritten public offering of 13,636,364 shares of common stock at a public offering price of $22.00 per share, before underwriting discounts and commissions. All of the shares of common stock are being offered by Revolution Medicines. In addition, Revolution Medicines has granted the underwriters a 30-day option to purchase up to an additional 2,045,454 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Revolution Medicines, are expected to be $300.0 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on March 7, 2023, subject to customary closing conditions.

Revolution Medicines Announces Pricing of $300.0 Million Public Offering of Common Stock

REDWOOD CITY, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that it has commenced an underwritten public offering to sell up to $300 million of shares of its common stock. All of the shares of common stock are being offered by Revolution Medicines. In addition, Revolution Medicines intends to grant the underwriters a 30-day option to purchase up to an additional $45 million of shares of common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Revolution Medicines Announces Commencement of Public Offering of Common Stock

Revolution Medicines, Inc. (NASDAQ:RVMD ) Q4 2022 Earnings Conference Call February 27, 2023 4:30 PM ET Company Participants Margaret Horn - Chief Operating Officer Mark Goldsmith - Chairman, President and Chief Executive Officer Steve Kelsey - President of Research and Development Jack Anders - Chief Financial Officer Conference Call Participants Faisal Khurshid - SVB Securities Michael Schmidt - Guggenheim Partners Marc Frahm - Cowen and Company, LLC Eric Joseph - JPMorgan Chase & Co. Benjamin Burnett - Stifel Financial Corp. Alec Stranahan - Bank of America Merrill Lynch Ami Fadia - Needham & Company Jay Olson - Oppenheimer & Co. Operator Good day, and thank you for standing by. Welcome to the Revolution Medicines Q4 Year-End 2022 Earnings Conference Call.

Revolution Medicines, Inc. (RVMD) Q4 2022 Earnings Call Transcript

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 25% and 127.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Tops Revenue Estimates

Early clinical data on RMC-6236 provided in support of RAS(ON) Inhibitor platform validation

Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress

REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2022 on Monday, February 27, 2023, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and full year, and provide an update on corporate progress.

Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2022 After Market Close on February 27, 2023

Does Revolution Medicines, Inc. (RVMD) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Revolution Medicines, Inc. (RVMD) is a Great Choice

REDWOOD CITY, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in two upcoming investor conferences. Mark A. Goldsmith, M.D., Ph.D., the company's chief executive officer and chairman, will be the featured speaker in fireside chats at the Guggenheim Healthcare Talks 2023 Oncology Conference and the SVB Securities Global Biopharma Conference.

Revolution Medicines to Participate in Upcoming Investor Conferences

Revolution Medicines, Inc. (RVMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Revolution Medicines, Inc. (RVMD): Can Its 15.9% Jump Turn into More Strength?

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Circle Pharma, a company focused on developing macrocycle therapeutics against targets previously considered to be undruggable, has appointed Stephen Kelsey as an independent member of its Board of Directors. Dr. Kelsey has extensive experience in oncology clinical development. He currently serves as president, head of research and development and chief medical officer at Revolution Medicines (NASDAQ:RVMD), and previously held roles including president of Onkaido Therapeutics, the oncology-focused unit of Moderna (NASDAQ:MRNA), senior vice president of new products at Medivation (acquired by Pfizer (NYSE:PFE)), executive vice president and chief medical officer at Geron Corporation (NASDAQ:GERN), vice president of oncology at Genentech (part of the Roche Group) and medical director at Pharmacia / SUGEN (acquired by Pfizer). Dr. Kelsey has had key roles in the development of many oncology therapeutics including Sutent®, Perjeta®, Kadcycla®, Erivedge® and imetelstat.

Circle Pharma Appoints Stephen Kelsey, MB ChB, MD, to its Board of Directors

Revolution Medicines, Inc. has a highly differentiated portfolio of RAS(ON) and RAS companion inhibitors that's standing up well in safety, efficacy. The company is well-capitalized to continue operations and clinical advancements.

Revolution Medicines: Highly Differentiated Offering Gaining Traction

Conduct and timing of ongoing Phase 2 study evaluating RMC-4630 in combination with sotorasib is expected to be unaffected Conduct and timing of ongoing Phase 2 study evaluating RMC-4630 in combination with sotorasib is expected to be unaffected

Revolution Medicines to Regain Global Rights to RMC-4630 following Sanofi's Termination of SHP2 Inhibitor Development and Commercialization Collaboration

Revolution Medicines, Inc. (NASDAQ:RVMD ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Margaret Horn - Chief Operating Officer Mark Goldsmith - Chairman & Chief Executive Officer Jack Anders - Senior Vice President of Finance & Principal Accounting Officer Steve Kelsey - President of R&D Conference Call Participants Alec Stranahan - Bank of America Faisal Khurshid - SVB Securities Eric Joseph - JPMorgan Marc Frahm - Cowen Michael Schmidt - Guggenheim Partners Chris Shibutani - Goldman Sachs Jay Olson - Oppenheimer Operator Good day and thank you for standing by. Welcome to the Revolution Medicines Third Quarter 2022 Earnings Webcast.

Revolution Medicines, Inc. (RVMD) Q3 2022 Earnings Call Transcript

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 0% and 60.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Misses Revenue Estimates

REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the third quarter 2022 on Monday, November 7, 2022, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a webcast to discuss the financial results for the quarter and provide an update on corporate progress.

Revolution Medicines to Report Financial Results for Third Quarter 2022 After Market Close on November 7, 2022

KRAS G12C (ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring KRAS G12C mutation

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company's First Mutant-Selective RAS(ON) Inhibitor

Company Promotes Jack Anders to Chief Financial Officer and Jeff Cislini to General Counsel

Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire

The consensus price target hints at a 45.4% upside potential for Revolution Medicines, Inc. (RVMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 45% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 31.9% in Revolution Medicines, Inc. (RVMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 32% Upside in Revolution Medicines, Inc. (RVMD): Here's What You Should Know

Revolution Medicines, Inc. (NASDAQ:RVMD ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants David Arrington - SVP of IR and Corporate Affairs Mark Goldsmith - Chairman and CEO Jack Anders - SVP, Finance and Principal Accounting Officer Steve Kelsey - President, Research and Development Conference Call Participants Marc Frahm - Cowen & Company Alec Stranahan - Bank of America Jonathan Chang - SVB Securities Neil Carnahan - Stifel Noah Eisenberg - JPMorgan Chase Operator Good day. My name is Christie, and I'll be your conference facilitator today.

Revolution Medicines, Inc. (RVMD) CEO Mark Goldsmith on Q2 2022 Results - Earnings Call Transcript

Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 5.75% and 4.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Tops Revenue Estimates

First two RAS(ON) Inhibitor drug candidates advance into clinical development

Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress

REDWOOD CITY, Calif., July 28, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the second quarter 2022 on Tuesday, August 9, 2022, after market close. At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines' senior management team will host a conference call and webcast to discuss the financial results for the quarter and provide an update on corporate progress.

Revolution Medicines to Report Financial Results for Second Quarter 2022 After Market Close on August 9, 2022

Underwriters' full exercise of option brings gross proceeds to $264.5 million Underwriters' full exercise of option brings gross proceeds to $264.5 million

Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

News for Revolution Medicines Stock (RVMD)